Perspective Therapeutics, Inc.CATXNYSE
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank57
3Y CAGR-35.6%
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

3Y CAGR
-35.6%/yr
vs +239.8%/yr prior
Acceleration
-275.4pp
Decelerating
Percentile
P57
Within normal range
vs 3Y Ago
0.3x
Contraction
Streak
3 yr
Consecutive declineDecelerating
PeriodValue
202513.60%
202426.34%
202348.19%
202250.81%
202132.17%
2020-5.51%
201910.16%
20180.38%
20179.59%
201621.18%